A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring hemodialysis (HD), and in participants with normal renal function.
Phase:
PHASE1
Details
Lead Sponsor:
Shionogi
Collaborator:
Biomedical Advanced Research and Development Authority